We next tested the DYRK1A protein levels across different subtypes of ALL and AML and, interestingly, observed increased DYRK1A expression in KMT2A-R ALL compared to the tested KMT2A wild-type leukemia cell lines and PDX cases (Supplementary Fig. 1F, G). Here, DYRK1A is linked to acute myeloid leukemia.